New survey on application of big data

HMA/EMA Joint Task Force on Big Data launches a survey on application of big data by industry across drug development pathway

The Heads of Medicines Agencies/European Medicines Agency (HMA/EMA) Joint Task Force on Big Data has launched a survey to ascertain the current landscape in terms of application of big data by Industry across the drug development pathway (human medicines only).

The results of the survey will be used to develop a future big data strategy and identify the future needs of the European Medicines Regulatory Network in this context.

The survey is available here. The deadline to contribute is 20 October 2017.


HMA/EMA Taskforce on Big Data:  a mandate of the taskforce is to explore a number of issues regarding the emerging challenges presented by big data in the regulation of medicinal products for human use.

Big Data: the term “big data” refers to extremely large sets of information, which require specialised computational tools to enable their analysis and exploitation. These data might come from:

  • data derived from clinical practice: e.g. electronic medical records, claims data, registries;
  • “omics” data: e.g. genomics, proteomics, metabolomics;
  • social media, m-health and other innovative and novel datasets;
  • clinical trials;
  • reports on spontaneous adverse reactions.

Date: 04/10/2017 | Tag: | News: 661 of 1573
All news


More news


More events

Subscribe to the VPH Institute Newsletter


Read all the newsletters of the VPH Institute